<li>5-htp<p>paroxetine and 5-htp both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>abiraterone<p>abiraterone increases levels of paroxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.</p></li><li>aceclofenac<p>paroxetine, aceclofenac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>acemetacin<p>paroxetine, acemetacin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>almotriptan<p>almotriptan and paroxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>amiodarone<p>amiodarone will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>amisulpride<p>amisulpride and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>amitriptyline<p>amitriptyline and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>amoxapine<p>amoxapine and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>amphetamine<p>amphetamine increases toxicity of paroxetine by serotonin levels. Use Caution/Monitor. Closely monitor for signs and symptoms of serotonin syndrome (eg, agitation, tremor, tachycardia).</p></li><li>artemether/lumefantrine<p>artemether/lumefantrine will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>artemether/lumefantrine and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>asenapine<p>asenapine will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>aspirin<p>paroxetine, aspirin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>aspirin rectal<p>paroxetine, aspirin rectal.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>paroxetine, aspirin/citric acid/sodium bicarbonate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>atomoxetine<p>paroxetine will increase the level or effect of atomoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Reduced initial doses of atomoxetine are recommended with strong CYP2D6 inhibitors.</p></li><li>axitinib<p>paroxetine increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>brexpiprazole<p>paroxetine will increase the level or effect of brexpiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Administer half of the usual brexpiprazole dose when coadministered with strong CYP2D6 inhibitors. If also administered with a strong/moderate CYP3A4 inhibitor, administer a quarter of brexpiprazole dose. NOTE: In MDD clinical trials, brexpiprazole dosage was not adjusted for strong CYP2D6 inhibitors (eg, paroxetine, fluoxetine); thus, CYP considerations are already factored into general dosing recommendations and brexpiprazole may be administered without dosage adjustment in patients with MDD.</p></li><li>buprenorphine subdermal implant<p>paroxetine, buprenorphine subdermal implant.
Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.</p></li><li>celecoxib<p>paroxetine, celecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>chlorpromazine<p>chlorpromazine and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>choline magnesium trisalicylate<p>paroxetine, choline magnesium trisalicylate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>cimetidine<p>cimetidine will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>clarithromycin<p>clarithromycin and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>clobazam<p>clobazam will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Lower doses of drugs metabolized by CYP2D6 may be required when used concomitantly. </p></li><li>clomipramine<p>clomipramine and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>clopidogrel<p>paroxetine increases effects of clopidogrel by pharmacodynamic synergism. Use Caution/Monitor. SSRIs affect platelet activation; coadministration of SSRIs with clopidogrel may increase the risk of bleeding.</p></li><li>clozapine<p>paroxetine increases levels of clozapine by decreasing metabolism. Use Caution/Monitor. Plasma levels of clozapine may be increased, resulting in increased pharmacologic and toxic effects. Adjust clozapine dose as needed when initiating or discontinuing certain SSRIs. .</p></li><li>cocaine<p>paroxetine and cocaine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>codeine<p>paroxetine will decrease the level or effect of codeine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Prevents conversion of codeine to its active metabolite morphine.</p></li><li>cyproheptadine<p>paroxetine increases and cyproheptadine decreases serotonin levels. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.</p></li><li>darunavir<p>darunavir decreases levels of paroxetine by Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Carefully titrate SSRI dose based on clinical  assessment of antidepressant response.</p></li><li>dasatinib<p>dasatinib and paroxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>defibrotide<p>defibrotide increases effects of paroxetine by Other (see comment). Use Caution/Monitor. 
Comment: Defibrotide may enhance effects of platelet inhibitors.</p></li><li>desipramine<p>desipramine and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>desvenlafaxine<p>desvenlafaxine will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses &lt;100 mg</p></li><li>dexfenfluramine<p>paroxetine will increase the level or effect of dexfenfluramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>paroxetine and dexfenfluramine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>dextroamphetamine<p>paroxetine will increase the level or effect of dextroamphetamine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>paroxetine and dextroamphetamine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>dichlorphenamide<p>dichlorphenamide and paroxetine both decrease  serum potassium. Use Caution/Monitor.</p></li><li>diclofenac<p>paroxetine, diclofenac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>diflunisal<p>paroxetine, diflunisal.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>dihydroergotamine<p>paroxetine and dihydroergotamine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>dihydroergotamine intranasal<p>paroxetine and dihydroergotamine intranasal both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>dofetilide<p>dofetilide and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>dolasetron<p>dolasetron and paroxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>donepezil<p>paroxetine will increase the level or effect of donepezil by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>dosulepin<p>dosulepin and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>doxepin<p>doxepin and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>dronedarone<p>dronedarone will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>dronedarone and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>droperidol<p>droperidol and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>eletriptan<p>eletriptan and paroxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>eliglustat<p>eliglustat increases levels of paroxetine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect.</p></li><li>eluxadoline<p>paroxetine increases levels of eluxadoline by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. As a precautionary measure due to incomplete information on the metabolism of eluxadoline, use caution when coadministered with strong CYP2D6 inhibitors.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of paroxetine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.</p></li><li>encainide<p>paroxetine will increase the level or effect of encainide by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>epinephrine<p>epinephrine and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>epinephrine racemic<p>epinephrine racemic and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>ergotamine<p>paroxetine and ergotamine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>erythromycin base<p>erythromycin base and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>erythromycin stearate<p>erythromycin stearate and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>etodolac<p>paroxetine, etodolac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>etoricoxib<p>paroxetine, etoricoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>fenbufen<p>paroxetine, fenbufen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>fenfluramine<p>paroxetine and fenfluramine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>fenoprofen<p>paroxetine, fenoprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>flecainide<p>flecainide and paroxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>flibanserin<p>paroxetine will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.</p></li><li>fluconazole<p>fluconazole and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>fluoxetine<p>fluoxetine and paroxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>flurbiprofen<p>paroxetine, flurbiprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>fluvoxamine<p>fluvoxamine and paroxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>formoterol<p>formoterol and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>fosamprenavir<p>fosamprenavir will decrease the level or effect of paroxetine by  increasing elimination. Use Caution/Monitor. Monitor response to paroxetine therapy closely</p></li><li>foscarnet<p>foscarnet and paroxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>frovatriptan<p>frovatriptan and paroxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>galantamine<p>paroxetine will increase the level or effect of galantamine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>green tea<p>green tea, paroxetine. Other (see comment). Use Caution/Monitor. 
Comment: Combination may increase risk of bleeding.</p></li><li>haloperidol<p>haloperidol will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>haloperidol and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>ibuprofen<p>paroxetine, ibuprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>iloperidone<p>iloperidone and paroxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>imatinib<p>imatinib will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>imipramine<p>imipramine and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>indomethacin<p>paroxetine, indomethacin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>ioflupane i 123<p>paroxetine decreases effects of ioflupane i 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration.</p></li><li>isoniazid<p>paroxetine and isoniazid both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>itraconazole<p>itraconazole and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>ivacaftor<p>paroxetine increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors .</p></li><li>ketoconazole<p>ketoconazole and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>ketoprofen<p>paroxetine, ketoprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>ketorolac<p>paroxetine, ketorolac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>ketorolac intranasal<p>paroxetine, ketorolac intranasal.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>l-tryptophan<p>paroxetine and l-tryptophan both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>lamotrigine<p>lamotrigine increases toxicity of paroxetine by unspecified interaction mechanism. Modify Therapy/Monitor Closely. CNS depressants may increase the toxic effects of selective serotonin reuptake inhibitors; psychomotor impairment may be enhanced.</p></li><li>lapatinib<p>lapatinib and paroxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>levofloxacin<p>levofloxacin and paroxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>lisdexamfetamine<p>paroxetine and lisdexamfetamine both increase  serotonin levels. Use Caution/Monitor.</p></li><li>lithium<p>paroxetine and lithium both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>lofepramine<p>lofepramine and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>lomitapide<p>paroxetine increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day.</p></li><li>loratadine<p>paroxetine will increase the level or effect of loratadine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>lorcaserin<p>lorcaserin will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>lornoxicam<p>paroxetine, lornoxicam.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>lsd<p>paroxetine and lsd both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>lumefantrine<p>lumefantrine will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>lumefantrine and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>lurasidone<p>lurasidone, paroxetine.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.</p></li><li>maprotiline<p>maprotiline and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>meclofenamate<p>paroxetine, meclofenamate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>mefenamic acid<p>paroxetine, mefenamic acid.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>meloxicam<p>paroxetine, meloxicam.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>methadone<p>methadone and paroxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>mianserin<p>mianserin and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>mipomersen<p>mipomersen, paroxetine.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.</p></li><li>mirabegron<p>mirabegron will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>mirtazapine<p>paroxetine and mirtazapine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>morphine<p>paroxetine and morphine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>moxifloxacin<p>moxifloxacin and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.<span><br><br></span>paroxetine and moxifloxacin both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>nabumetone<p>paroxetine, nabumetone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>naproxen<p>paroxetine, naproxen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>naratriptan<p>naratriptan and paroxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>nilotinib<p>nilotinib and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>nortriptyline<p>nortriptyline and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>octreotide<p>octreotide and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>octreotide (antidote)<p>octreotide (antidote) and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>ofloxacin<p>ofloxacin and paroxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>oxaprozin<p>paroxetine, oxaprozin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>oxycodone<p>oxycodone increases effects of paroxetine by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Opioids may enhance the serotonergic effects of SSRIs and increase risk for serotonergic syndrome.</p></li><li>paliperidone<p>paliperidone and paroxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>parecoxib<p>paroxetine, parecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>peginterferon alfa 2b<p>peginterferon alfa 2b, paroxetine. Other (see comment). Use Caution/Monitor. 
Comment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate.</p></li><li>pentazocine<p>paroxetine and pentazocine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>perhexiline<p>paroxetine will increase the level or effect of perhexiline by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>piroxicam<p>paroxetine, piroxicam.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>posaconazole<p>paroxetine and posaconazole both increase  QTc interval. Use Caution/Monitor.</p></li><li>prochlorperazine<p>paroxetine will increase the level or effect of prochlorperazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>prochlorperazine and paroxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>promazine<p>paroxetine will increase the level or effect of promazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>promazine and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>promethazine<p>promethazine and paroxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>protriptyline<p>protriptyline and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>quinidine<p>quinidine will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Monitor patients for signs of paroxetine toxicity. Paroxetine doses may need to be reduced.</p></li><li>ranolazine<p>paroxetine and ranolazine both increase  QTc interval. Use Caution/Monitor.</p></li><li>risperidone<p>paroxetine will increase the level or effect of risperidone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>paroxetine and risperidone both increase  QTc interval. Use Caution/Monitor.<span><br><br></span>paroxetine increases levels of risperidone by decreasing metabolism. Use Caution/Monitor.</p></li><li>ritonavir<p>ritonavir will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>rizatriptan<p>rizatriptan and paroxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>safinamide<p>paroxetine, safinamide.
Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Monitor patients for symptoms of serotonin syndrome if SSRIs are coadministered with safinamide.</p></li><li>salicylates (non-asa)<p>paroxetine, salicylates (non-asa).
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>salsalate<p>paroxetine, salsalate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>same<p>paroxetine and same both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>sertindole<p>paroxetine and sertindole both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate<p>paroxetine, sodium sulfate/potassium sulfate/magnesium sulfate. Other (see comment). Use Caution/Monitor. 
Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol<p>paroxetine, sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol. Other (see comment). Use Caution/Monitor. 
Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.</p></li><li>sulfamethoxazole<p>sulfamethoxazole and paroxetine both increase  QTc interval. Use Caution/Monitor.</p></li><li>sulfasalazine<p>paroxetine, sulfasalazine.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>sulindac<p>paroxetine, sulindac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>sumatriptan<p>sumatriptan and paroxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>sumatriptan intranasal<p>sumatriptan intranasal and paroxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>sumatriptan transdermal<p>sumatriptan transdermal and paroxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>tamoxifen<p>paroxetine decreases effects of tamoxifen by decreasing metabolism. Use Caution/Monitor. Inhibition of CYP2D6 metabolism to tamoxifen's active metabolite, endoxifen.</p></li><li>tamsulosin<p>paroxetine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>tapentadol<p>paroxetine and tapentadol both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>telavancin<p>paroxetine and telavancin both increase  QTc interval. Use Caution/Monitor.</p></li><li>telithromycin<p>paroxetine and telithromycin both increase  QTc interval. Use Caution/Monitor.</p></li><li>tetrabenazine<p>paroxetine increases effects of tetrabenazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Decrease tetrabenazine dose by 50% when coadministered with strong CYP2D6 inhibitors.</p></li><li>tolfenamic acid<p>paroxetine, tolfenamic acid.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>tolmetin<p>paroxetine, tolmetin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>tramadol<p>paroxetine decreases effects of tramadol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Decreased conversion of tramadol to active metabolite.<span><br><br></span>paroxetine and tramadol both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>trazodone<p>trazodone and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>trifluoperazine<p>paroxetine will increase the level or effect of trifluoperazine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>trifluoperazine and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>trimethoprim<p>paroxetine and trimethoprim both increase  QTc interval. Use Caution/Monitor.</p></li><li>trimipramine<p>trimipramine and paroxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>tropisetron<p>paroxetine will increase the level or effect of tropisetron by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>paroxetine and tropisetron both increase  QTc interval. Use Caution/Monitor.</p></li><li>valerian<p>valerian and paroxetine both increase  sedation. Use Caution/Monitor.</p></li><li>venlafaxine<p>paroxetine and venlafaxine both increase  QTc interval. Use Caution/Monitor.</p></li><li>vorapaxar<p>paroxetine, vorapaxar.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive antiplatelet effect may occur; SSRIs and SNRIs may cause platelet serotonin depletion .</p></li><li>voriconazole<p>paroxetine and voriconazole both increase  QTc interval. Use Caution/Monitor.</p></li><li>ziprasidone<p>paroxetine and ziprasidone both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>zolmitriptan<p>zolmitriptan and paroxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li>